117TH CONGRESS 1ST SESSION

H. R. 5988

To restrict the use of Federal Funds for gain-of-function research in the People's Republic of China.

IN THE HOUSE OF REPRESENTATIVES

NOVEMBER 16, 2021

Mr. Stewart (for himself, Mr. Jackson, and Ms. Malliotakis) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committees on Science, Space, and Technology, Oversight and Reform, and Foreign Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL

To restrict the use of Federal Funds for gain-of-function research in the People's Republic of China.

- 1 Be it enacted by the Senate and House of Representa-
- 2 tives of the United States of America in Congress assembled,
- 3 SECTION 1. SHORT TITLE.
- 4 This Act may be cited as the "Fairness and Account-
- 5 ability in Underwriting Chinese Institutions Act" or the
- 6 "FAUCI Act".

1	SEC. 2. RESTRICTIONS ON FEDERAL FUNDING OF CERTAIN
2	GAIN-OF-FUNCTION RESEARCH.
3	(a) Gain-of-Function Research Definition.—In
4	this section, the term "gain-of-function research" means
5	any research that—
6	(1) may be reasonably anticipated to confer at-
7	tributes to influenza, MERS, or SARS viruses such
8	that the virus would have enhanced pathogenicity or
9	transmissibility in any organism; or
10	(2) involves the enhancement of potential pan-
11	demic pathogens or related risky research with po-
12	tentially dangerous pathogens.
13	(b) Funding Limitations.—
14	(1) In general.—Notwithstanding any other
15	provision of law, no Federal funding may be made
16	available for any purpose, including under any con-
17	tract, grant, subgrant, or other assistance, to labora-
18	tories or research institutions in the People's Repub-
19	lic of China for the purposes of gain-of-function re-
20	search.
21	(2) Certification.—Any recipient of Federal
22	funding for the purposes of scientific research shall
23	certify to the issuing authority that such recipient
24	will not distribute any such Federal funds, whether
2.5	directly or through subgrants to any qualifying lab-

oratory or research institution that is in the People's

26

- 1 Republic of China or that receives any funding from
- 2 the People's Republic of China, for the purposes of
- 3 gain-of-function research.
- 4 (c) Penalty for Lack of Candor.—With respect
- 5 to any official or employee of the National Institutes of
- 6 Health, or grantee or employee or contractor of a grantee
- 7 of the National Institutes of Health, who is determined
- 8 by the Inspector General of the Department of Health and
- 9 Human Services to have intentionally misled, or omitted
- 10 information in a disclosure to, Congress, the National In-
- 11 stitutes of Health, or any relevant Inspector General about
- 12 the direction, scope, or extent of Federal funding of inter-
- 13 national gain-of-function research, in addition to being
- 14 subject to all other applicable criminal penalties—
- 15 (1) such person shall not be eligible for any new
- 16 Federal grant or other funding;
- 17 (2) if such person previously received a Federal
- grant or other funding, such grant or other funding
- shall be immediately terminated and any unexpended
- funds shall be rescinded; and
- 21 (3) such person shall not be eligible for Federal
- employment.
- 23 (d) REPORT REQUIRED.—Not later than 30 months
- 24 after the date of enactment of this Act, the Office of
- 25 Science and Technology Policy, in consultation with the

- 1 Department of Health and Human Services, the Depart-
- 2 ment of Homeland Security, the Department of Justice,
- 3 the Director of National Intelligence, and the Department
- 4 of State, shall submit, in both classified and unclassified
- 5 forms, a report to the appropriate committees of Congress
- 6 providing an assessment of—
- 7 (1) the United States capacity to determine the 8 extent of gain-of-function research conducted by any 9 laboratories of research institutions in the People's 10 Republic of China, including the Wuhan Institute of 11 Virology, and safety protocols followed by labora-12 tories or research institutions in the People's Repub-13 lic of China, including the Wuhan Institute of Virol-14 ogy, in conducting any gain-of-function research;
 - (2) the United States capacity to determine whether cooperation or relationships between laboratories or research facilities in the People's Republic of China conducting gain-of-function research and the People's Liberation Army exist;
 - (3) costs and potential risks or benefits of any United States cooperation or funding with laboratories or research facilities in the People's Republic of China conducting gain-of-function research;
- 24 (4) a recommendation of whether the United 25 States should resume or continue to suspend any co-

15

16

17

18

19

20

21

22

23

- operation or funding of laboratories or research facilities in the People's Republic of China conducting gain-of-function research;
 - (5) a list of all gain-of-function research currently being funded with financial support of any agency of the Federal Government, including the purpose, cost, pathogens, and location of research;
 - (6) a detailed list of all Federal funding for research being conducted in or with the People's Republic of China; and
 - (7) a determination of whether the Chinese laboratories identified in the report have had, or continue to have, a connection to the proliferation of fentanyl and fentanyl-analogues in the United States.
- 16 (e) National Security Waiver.—The President
 17 may waive the limitation under subsection (b) with respect
 18 to particular research described in such subsection upon
 19 a determination that such a waiver would be in the na20 tional security interest. Such waiver shall be made publicly
 21 available at the time of its issuance.

4

5

6

7

8

9

10

11

12

13

14

15